BioSpace News Archive

This milestone marks the fifth study for IMBRUVICA to bring a chemo-free treatment option to patients with CLL and the sixth approval for IMBRUVICA in CLL

Statewide assessment will help prioritize those who need COVID-19 tests, schedule test appointments, and manage the spread of the virus

OncoImmune, Inc. initiated its Phase III clinical trial testing the safety and efficacy of CD24Fc in hospitalized COVID-19 patients at the University of Maryland Baltimore Medical Center on April 20, 2020.

Myovant Sciences announced it will hold a webcast and conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on Wednesday, April 22, 2020, to discuss results from the Phase 3 SPIRIT 2 study of once-daily relugolix combination therapy in women with pain associated with endometriosis.

Advances Discovered in Collaboration with University Hospital Basel’s Liechti Laboratory and Aims To Enhance Therapeutic Potential of Psychedelics

Medifast, Inc. (NYSE: MED), a leading manufacturer and distributor of clinically proven programs and healthy living products, will announce financial results for the first quarter ended March 31, 2020 on Tuesday, May 5, 2020, after market close

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced that it will report financial results for the first quarter of 2020 after market close on Tuesday, May 5, 2020.

Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced today that the United States Court of Appeals for the Federal Circuit has upheld the United States District Court for the District of Delaware’s decision that Banner’s BAFIERTAM™ product does not infringe the extended portion (under the Hatch-Waxman Act) of U.S. Patent Number 7,619,001 (the “‘001 patent”) which protects Biogen’s product Tecfidera®.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Northern Biologics for semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of Northern Biologics’ lead preclinical antibody for the treatment of cancer.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has begun to perform antibody testing for coronavirus (COVID-19) using blood samples.